Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738452 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00738452 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00738452, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin, paclitaxel, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies can find tumor cells and carry tumor-killing substances to them without harming normal cells. Giving radiation therapy and combination chemotherapy together before radiolabeled monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of radiolabeled monoclonal antibody therapy when given after radiation therapy and combination chemotherapy in treating patients with stages I-IIIB non-small cell lung cancer.
Interventions
- OTHER pharmacological study
- RADIATION radiation therapy
- PROCEDURE radionuclide imaging
- OTHER high performance liquid chromatography
- PROCEDURE single photon emission computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-08-06 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738452
The ClinicalTrials.gov registry entry for NCT00738452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00738452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738452 about?
NCT00738452 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy". RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin, paclitaxel, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoc...
What is the current status of trial NCT00738452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-08-06. Estimated completion is 2018-02-07.
What interventions are being tested in trial NCT00738452?
The interventions under investigation include: pharmacological study (OTHER), radiation therapy (RADIATION), radionuclide imaging (PROCEDURE), high performance liquid chromatography (OTHER), single photon emission computed tomography (PROCEDURE).
Who is sponsoring clinical trial NCT00738452?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.